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Abstract
Solitary fibrous tumor (SFT), is a rare mesenchymal spindle cell tumor and its biological behavior is 
hard to predict. There is no characteristic clinical manifestation and morphologic features showed broad 
spectrum, so often diagnosed as other spindle cell mesenchymal tumor, benign or malignant. In most cases, 
immunohistochemistry staining (IHC) is needed to diagnose SFT. The aim of this retrospective study is to 
see demographic data, histopathological features and the importance of IHC staining diagnosis of SFT. 
Secondary data was obtained from Department of Anatomical Pathology, Faculty of Medicine, Universitas 
Indonesia in 2010-2016. There were 35 samples included in this review; most are male (20 cases) aged <55 
years old. Thirty one cases were in the extrapleural site and most of the tumor is less than 5 cm in diameter. 
There are 20 cases of cellular SFT while the other is fibrous SFT. Commonly, cellular SFT shows moderate 
cellularity and pleiomorphism. Fibrous SFT are well circumscribed and without necrosis. There are only 3 
cases of malignant SFT which is located in intra-abdominal and orbit. Generally, SFT is benign, small, and 
well circumscribed. Most of the cases are cellular than fibrous; mild to moderate nuclear pleiomorphism, 
mitotic activity low, and without necrotic. Features of malignant SFT are hypercellularity, moderate to high 
nuclear pleiomorphism, mitotic >4/10 high power field (HPF) and necrosis. Most SFT are benign, some may 
recurrence and metastasize.
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Solitary Fibrous Tumor: Studi Retrospektif Gambaran Histopatologis dan
Pulasan Imunohistokimia di Rumah Sakit Cipto Mangunkusumo
Abstrak
Solitary fibrous tumor (SFT), tergolong tumor mesenkimal jenis sel spindel yang jarang ditemukan dan 
sifat biologiknya sulit diprediksi. Gambaran klinik SFT tidak khas dan gambaran morfologiknya berspektrum 
luas sehingga sulit dibedakan dengan tumor mesenkimal sel spindel yang lain baik jinak maupun ganas. Pada 
sebagian besar kasus, diperlukan pemeriksaan imunohistokimia (IHK) untuk menegakkan diagnosis SFT 
dan menyingkirkan diagnosis banding. Studi retrospektif ini bertujuan mengetahui karakteristik demografik, 
gambaran histopatologik dan pentingnya pulasan IHK dalam mendiagnosis SFT. Data sekunder berasal 
dari catatan medik Departemen Patologi Anatomik FKUI/RSCM tahun 2010-2016. Gambaran histopatologik 
yang dinilai meliputi simpai, pola histopatologik, selularitas, pleomorfisme, mitosis, nekrosis, rekurensi serta 
metastasis. Dari 35 sampel yang dapat dianalisis terdapat lebih banyak subjek  laki-laki yaitu 20 kasus dan usia 
<55 tahun yaitu 29 kasus. Lokasi ekstrapleura lebih banyak ditemukan  yaitu 31 kasus dibandingkan pleura 
(4 kasus). Tumor berukuran kecil (<5 cm) lebih banyak yaitu 21 kasus. Sebagian besar SFT berbatas tegas 
dan SFT selular lebih banyak dari fibrous, yaitu 33:13. SFT selular umumnya menunjukkan selularitas tinggi 
dengan pleomorfisme sedang, sedangkan SFT fibrous dengan selularitas dan pleomorfisme sedang. Mitosis 
0/10 LPB dan tanpa nekrosis. Didapatkan 3 kasus yang memenuhi kriteria SFT ganas dengan hiperselularitas 
inti pleomorfik, nekrosis dan mitosis >4/10LPB. Rekurensi ditemukan pada 5 SFT jinak.
Kata kunci: solitary fibrous tumor; selular; fibrous; maligna; imunohistokimia
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Introduction
Solitary fibrous tumor (SFT) is fibroblastic 
mesenchymal tumor; occur in <2% of all soft tissue 
tumor and <5% of all pleural primary tumor.1,2 
Patients aged were range from 20-70 years old and 
reach highest incident in 5th decade. No gender 
predilection was found. Extrapleural SFT can be found 
in subcutaneous tissue, inner extremities soft tissue, 
retroperitoneum, abdominal cavity, head and neck 
including orbital, meninges and visceral organs such 
as thyroid, liver, gastrointestinal track, prostate and 
salivary glands.3-5
SFT is a grayish, solitary, multinodular, well 
circumscribe mass with 5-10 cm in diameter and 
located subcutaneous. Histologically, it shows 
patternless architecture with combination of cells 
and fibrous stroma. It shows both hypercellular and 
hypocellular area with collagenous and hyalinised 
stroma. In some cases, staghorn and hyalinised 
vessels can be prominent. The nucleus is oval to 
spindle, with a little cytoplasm with indistinct borders. 
Malignant SFT is characterized with high celullarity, 
increase mitotic activity (more than 4/10 HPF), nuclear 
pleiomorphism, necrosis, and infiltrative border.6-8
SFT is a slow growing tumor, with clinical 
manifestations may arise from pressure effect to 
nearby organs. Hypoglycemia is present in 5% 
cases of SFT due to the production of insulin-like 
growth factor (IGF).5-9 Imaging studies such as CT-
scan and MRI show non-specific well circumscribed 
masses with heterogeneous intensity.10
It is difficult to diagnose SFT histopathologically 
only, because their morphology is unspecific, pattern 
less, from fibrous to cellular. Differential diagnoses 
for SFT are mesenchymal tumors with staghorn 
vessel and perivascular hyalinization, cellular 
schwannoma, benign fibrous histiocytoma, spindle 
cell lipoma, hemangioma, monophasic synovial 
sarcoma, malignant peripheral nerve sheath tumor 
(MPNST) and dedifferentiated liposarcoma. 
SFT can be confirmed by immunohistochemistry 
(IHC) staining using CD34, CD99 and Bcl-2, 
although less specific. About 5-10% cases show 
negative CD34 staining.11 The most sensitive and 
specific IHC staining for SFT is STAT6, known by 
genes fusion NAB2 and STAT6.12-14
Most of SFT are benign but the behavior of this 
tumor is unpredictable. Recurrence and metastatis 
occur in 5-10% cases of benign SFT and 20-30% 
cases of malignant SFT.3 Although there is no 
association between histopathology features to 
the behavior of the tumor, high mitotic activity in 
malignant SFT is an indicator of poor prognosis.1 
Complete excision and long term follow up is 
required in both benign and malignant SFT.
The purpose of this review is to describe the 
demographic and histopathological features of SFT 
that resemble other spindle cell tumor (benign or 
malignant) and the importance of immunostaining to 
exclude differential diagnosis. 
Methods
This is a retrospective, descriptive, cross 
sectional study. Secondary data were obtained 
from the medical record of the Department of 
Anatomical Pathology, Faculty of Medicine, 
Universitas Indonesia, Dr. Cipto Mangunkusumo 
Hospital from January 2010 to December 2016. The 
morphological code used according to International 
Classification of Disease-10 (ICD-10) was M8815/1 
and M8815/3 for malignant SFT and M.9150/0, 
M.9150/1 and M.9150/3 for hemangiopericytoma for 
archive before 2013. Tumors were taken from any 
site of body through biopsy or surgical procedure. 
All requisitions forms, histopathology slides and 
IHC slides were collected and reviewed by the 
researchers (NCS and AA).
The inclusion criteria for the study are all cases 
diagnosed as SFT or hemangiopericytoma by H&E 
staining and/or IHC. Incomplete or unrepresentative 
slides and SFT/HPC located in central nervous 
system are excluded from the study. 
The researchers review H&E slides for tumor 
borders, pattern, cellularity, nucleus pleiomorphism, 
necrosis, mitotic activity as in Demicco,16 and IHC. 
We also evaluate the recurrence and metastatis.
Results
There were 53 cases of SFT and 
hemangiopericytoma retrieved in this study. 
Eighteen cases (ten with incomplete data and eight 
cases were located at CNS) were excluded from 
the review. Demographic characteristic, size and 
location of the tumor were recorded. From 35 cases, 
27 of them have been confirmed by IHC staining. 
Most of the patients were male and above 50 years 
old. Demographic and characteristic of SFT is shown 
in Table 1.
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Table 1. Patients Demographic and Characteristic of SFT
Characteristic n
Age 
<55 year old 29
≥55 year old 6
Sex
Male 20
Female 15
Location
Pleural 4
Extra pleural 31
Head-neck 23
Extremities 2
Intra-abdomen 5
Trunks 1
Size in diameter 
<5 cm 21
5-10 cm 8
>10 cm 6
Procedure
Operation 26
Biopsy 9
Microscopically, SFT is pattern less, tumor 
dominated with cellular or fibrous component. (Fig. 
1) Most of the tumors features between cellular 
and fibrous component, with moderate cellularity 
and pleiomorphism, with no mitotic activity. There 
were only 3 cases diagnosed as malignant SFT 
(Fig. 1F). Criteria of malignancy in the SFT based 
on WHO classification of soft tissue and bone tumor 
is characterized by increased cellularity, mitoses 
>4/10 HPF, nuclear pleiomorphism, necrosis and or 
infiltrative border.
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Figure 1.  Histopathology of SFT. A. Well circumscribed tumor → (40x). B. Cellular SFT: uniform tumor cell, 
staghorn vessels →(40x). C. Fibrous SFT: patternless, hypocellular (   ) and hypercellular (   ) (40x). D. 
Perivascular hyalinization → (40x). E. Oval to spindle shape nuclei (400x). F. Malignant SFT with nuclear 
pleiomorphism with mitotic activity → (400x)
Both cellular and fibrous SFT have well 
circumscribed border, moderate cellularity and mild 
to moderate nuclear pleiomorphism. Necrosis was 
found in all malignant cellular SFTs and one case 
of benign fibrous SFT (Table 2). From 3 malignant 
SFTs, two are located intra- abdomen and the 
other is located in orbit. All of malignant cases 
size were >5 cm and mitoses >3/10 HPF, with 
moderate to high cellularity and prominent nuclear 
pleiomorphism.
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Table 2. Comparison between Cellular and 
Fibrous SFT
Histopathologic 
features
Cellular SFT
(n=22)
Fibrous SFT
(n=13)
Border
Well circumscribed 13 11
Poorly circumscribe/
infiltrative
9 2
Cellularity
Mild 4 3
Moderate 13 8
High 5 2
Pleomorphisme
Mild 7 4
Moderate 12 9
Severe 3 0
Mitosis
0/10 HPF 19 11
1-3/10 HPF 0 2
≥ 4/10 HPF 3 0
Necrosis
Negative/minimal 
(<10 %)
19 12
Positive (≥10 %) 3 1
Recurrence 3 2
Mitosis 0 0
Twenty seven of 35 cases were stained with 
IHC to confirm the diagnosis. CD34 is the most 
common IHC used. Only 13 cases (9 cellular SFT 
and 4 fibrous SFT) were completely stained with 
combination of CD34, CD99 and Bcl-2. (Table 3). 
CD34, CD99 and Bcl-2 were considered positive 
if more than 10% areas of the tumor cells were 
strongly stained (Fig. 2). All of the antibodies showed 
diffuse staining in SFT. IHC is also used to exclude 
differential diagnosis.
Table 3. IHC Staining of Cellular SFT and Fibrous 
IHC Staining
Cellular (n=9) Fibrous (n=4)
Positive Positive
CD34 9/9 3/4
CD99 8/9 3/4
Bcl-2 8/9 3/4
Ki-67>15% 2/9 0/4
  
            
Figure 2. Immunoprofile of SFT. A. CD34, positive diffuse in cytoplasm. B. CD99 positive diffuse in membrane. C. 
Bcl-2 positive diffuse in membrane and cytoplasm. D. Ki67 in malignant SFT, positive diffuse in 79% nuclei 
(IHC, 400x).
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Discussions
Previously, SFT can be found in serous tissue 
such as in pleural, pericardial and peritoneal. 
However, later, SFT can be found anywhere.15-17 
Ratio between pleural and extra- pleural SFT has 
not been documented well due to limited cases. Both 
have similar clinical manifestation and microscopic 
appearance.3,7 Gold et al1 reported 30-40% cases of 
SFT were extrapleural. Outside thorax cavity, SFT is 
commonly found in soft tissue extremities and orbit.
In this review, we found 31 cases of extrapleural 
SFT (89%) and only 4 cases (11%) pleural SFT. From 
31 cases of extrapleural SFT, majority of the cases 
(23 cases) are located in head and neck, 5 cases 
in intra-abdomen/pelvis, 2 cases in the extremities 
and one case in the trunk. Tumor location is not in 
line with the result of Demicco et al16 who studied 
110 cases of SFT and found less pleural than 
extrapleural SFT (31:79 cases). However, most of 
their extrapleural SFT are located in the abdomen 
(37 cases), followed by 18 cases in the extremities 
and 12 cases in head-neck and trunks.
Of the 23 cases of head-neck SFT, there are 16 
cases located in the orbit. Westra et al18 first reported 
orbital SFT in 1994. Kao et al19 reported 36 cases of 
head-neck SFT composed of 12 cases of oral cavity, 
11 from orbital, 6 from nasal and 7 cases of head-
neck soft tissue. Orbital SFT may originate from the 
lacrimal sac, lacrimal fossa, conjunctiva and sclera. 
In 2010-2016, there is an increase number of SFT 
diagnosed with the highest number in 2016.15,20
Molecular studies of SFT have been started 
in 2014. Fritchie et al21 proved there were NAB2-
STAT6 gene fusion in >95% of SFT including 
meningeal hemangiopericytoma. Doyle et al14 
reported expression of STAT6 in the nuclei in 98% 
cases of SFT can be used as a surrogate marker of 
NAB2-STAT6 gene fusion. Various studies showed 
the same result.11-13,22
From 35 cases of SFT, 20 cases are male and 
15 cases are female. Median age of the patients is 39 
years old (range 14-68 years old). According to the 
literature, the ratio of male and female is 3:2 ranged 
in 20-70 years old.3 The tumor rarely occurred in 
children and elderly. The youngest patient with SFT 
is 2 years old.23 In our study, the youngest patient is 
14 years old.
A total of 21 cases (60%) in our study were <5 cm 
in diameters. Eight cases were measured between 
5-10cm, and 6 cases with size more than 10cm and 
located in intra- abdomen and extremities. Gold et al1 
reported tumor size > 10cm is correlated with poorer 
prognosis.  Unfortunately we did not have follow up 
data of the patient, except for 5 cases that recidive 
in 1-2 year time. A multicenter study conducted by 
Von Houdt et al24 reported that tumor size more than 
10 cm and increase mitotic activity are correlated 
to a significant increase of metastatic. Bishop et 
al25 studied 13 cases of malignant reported that the 
average size of tumor is 13,4 cm and can be located 
in at any site of the body.
Malignancy criteria of SFT were originally 
described by Vallat-Decouvelaere et al26 based on 
nuclear pleiomorphism, hypercellularity, mitoses 
≥4/10 HPF, and necrosis. WHO classification of 
soft tissue and bone tumor criteria for malignant 
SFT are: hypercellularity, mitoses ≥4/10 high power 
fields, pleiomorphic nuclei, necrosis and or infiltrative 
border.15 Marino-Enriquez at al9 stated that higher 
mitosis is the most reliable criteria of malignant SFT.
In this study, we found that fibrous SFT shows 
moderate cellularity and moderate pleomorphism, 
while cellular SFT shows high cellularity and 
moderate pleomorphism. Demicco et al12 concluded 
fibrous SFT showed high cellularity, moderate 
pleomorphism and cellular SFT are dominated by 
high cellularity and mild pleomorphism.
There are 3 variants of SFT: 1) classic pattern 
less with spindled to ovoid fibroblastic cells, 
prominent vascular pattern, varying component 
of fibrous stroma and occasional multinucleated 
stromal giant cells (giant cell angiofibroma) (Fig 
3A and 3B) and lipomatous (fat-forming) SFT, 2) 
malignant SFT, and 3) dedifferentiated SFT. 7,9
We found 3 interesting cases in this review. 
First is a giant cell-rich SFT (formerly known as 
giant cell angiofibroma). Clinical presentation as a 
mass in right ear canal. At first it was diagnosed as 
a HPC. After reevaluation, it was diagnosed as a 
mesenchymal tumor that difficult to determine the 
origin and type of the malignancy and final diagnosis 
without IHC is a soft tissue tumor suspect malignancy 
with differential diagnosis of malignant peripheral 
nerve sheath tumor (MPNST) and inflammatory 
myofibroblastic tumor. IHC staining shows diffuse 
CD34 and CD99 positive tumor cell and only 1-2% 
positivity in Ki-67 staining. Based on this finding the 
case is diagnosed as SFT.9
Second case is consultation from other 
hospital, a retroperitoneal mass that initially was 
diagnosed as a hemangiopericytoma in 2014. After 
reviewing the H&E slide, we favored as malignant 
myopericytoma and angiosarcoma as differential 
diagnosis. Immunostaining was performed and the 
result showed strong, diffuse vimentin and CD34 
positivity, also positive for neuron specific enolase 
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(NSE), moderately positive with smooth muscle 
actin (SMA), negative with CD31, muscle-specific 
actin (MSA) and desmin, S100 non-specific, and 
Ki67 < 10%. IHC result concluded the case as SFT.
Third case is a lobulated sinonasal mass, 
initially diagnosed as a malignant tumor (MPNST) 
possibly due its clinical appearance. EMA, CD99 
and Bcl-2 staining are positive and Ki-67 positive for 
10% of cells, while CD34, CD31 and SMA staining 
were negative. Even the IHC staining is not typical, 
morphologic and IHC staining concluded this case as 
a SFT. Unfortunately confirmation using STAT6 was 
not done because it is not available in our institute.
IHC examination in this review showed all cases 
of cellular SFT are positive stained with CD34, 89% 
stained with CD99 and 89% stained with Bcl-2. While 
fibrous SFT were only 75% stained with CD34; CD99, 
and Bcl-2. We found diffuse positivity in both cellular 
and fibrous SFT. Goldblum et al 7 reported that cellular 
SFT only positive for CD34 in fewer cases, stained 
weak and less diffuse rather than fibrous SFT. In 
contrast, previous studies showed that SFT express 
CD34 in 90% cases, CD99 in 70% cases and Bcl-2 in 
only 30% cases. CD34 negative were found in 5-10% 
cases of SFT and cannot exclude the SFT diagnosis.9 
Schulz et al27 reported weak expression of CD34 
in malignant SFT. Negative CD34 staining were 
found in recurrent tumor and malignant transformed 
tumor.28,29 STAT6 staining has >95% sensitivity and 
100% specificity for diagnose SFT.11,13,14
Differential diagnosis for SFT, such as cellular 
schwannoma showed strong diffuse positive staining 
with S-100. Monophasic synovial sarcoma is usually 
positive with CD99 and Bcl-2 but negative for CD34 
(95% cases) and strong positive with TLE1. MPNST 
is focally positive with S-100 and 50% cases positive 
glial fibrillary acidic protein (GFAP). Other tumor 
which are usually positive for CD34 is (1) Spindle 
cell lipoma consist of fat cell and positive diffuse 
with CD34, although the staghorn vessel is less in 
spindle cell lipoma. (2) Deep fibrous histiocytoma 
is generally firmly and positive CD34 staining but it 
shows storyform pattern, while SFT is pattern less. 
(3) Hemangioma is positive for CD31 and glucose 
transporter-1 (GLUT-1).9
We found recurrence in 3 cases of benign SFT 
located in orbit (2 cases) and sinonasal (1 case). 
Baldi et al29 studied 14 cases of late recurrence SFT 
(recurrent occur after 10 years of first diagnosis), 
they found five of the cases were formerly benign 
and other seven cases were formerly malignant. 
They also found 4 from 5 metastatic cases were 
benign SFT. They concluded that recurrence may 
occur form benign SFT. Local recurrence incidence 
in 10 and 20 years are 19,2% and 38,6% while 
metastatic recurrence incidence in 10 and 20 years 
are 31,4% and 49,8%. Long term monitoring is 
necessary for SFT.30
Conclusions
SFT were found more in male than female. 
Extrapleural SFT is more common than pleural SFT. 
Majority of SFT is benign, with <5 cm in diameter 
and well circumscribed, with cellular pattern is most 
common. Cellular type is more common than fibrous 
type. Recurrence is more common in orbit area and 
malignant SFT is in intra-abdominal (pleural SFT) 
and orbit. IHC staining is required for the diagnosis 
SFT and exclusion of differential diagnosis. 
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